Entheon Biomedical (XCNQ:ENBI) Short-Term Debt & Capital Lease Obligation : C$0.00 Mil (As of Nov. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Entheon Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was C$0.00 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Entheon Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was C$0.00 Mil.

Entheon Biomedical Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Entheon Biomedical's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Short-Term Debt & Capital Lease Obligation Chart

Entheon Biomedical Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Nov21

Nov22

Nov23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

Entheon Biomedical Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	-	-

Entheon Biomedical Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Entheon Biomedical Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Entheon Biomedical (XCNQ:ENBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ENTBF:USA 1XU1:Germany

Address

999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5

Website

https://www.entheonbiomedical.com

Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines